ASSESSMENT OF MATRIX METALLOPROTEINASES AND THEIR TISSUE INHIBITORS FOR NON-INVASIVE DIAGNOSIS OF LIVER FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE

Objective: To evaluate the diagnostic value of MMP-9, TIMP-1 and 2 as non-invasive markers of liver fibrosis in the NAFLD to improve the management of patients with this pathology. Materials and methods. We examined 99 patients with NAFLD and different stages of fibrosis, 83 men, 16 women, median age 45 (range 40-55) years. We assessed of risk factors for liver fibrosis in the NAFLD, anthropometric indicators, biochemical analysis of blood, abdominal ultrasonic studies, the levels of MMP-9, TIMP-1 and 2. Depending on the stage of fibrosis (0-4), established as a result of liver elastometry (Fibroscan), patients were divided into 5 groups: n = 27, n = 22, n = 23, n = 14, n = 13, respectively. Results. Between the groups in medical history, physical examination, calculation of BMI and the ratio of waist to hip volume (W/H) no significant differences were found. 64,6% of patients had abdominal obesity (BMI - 31,5 (29,1-33,9), W/H - 1,02 (1,01-1,05). Obesity and abdominal obesity (BMI, W/H) had a significant positive relationship of moderate streight (rs = (0,257), p < 0,04, rs = (0,301), p < 0,02, respectively), with the stage of liver fibrosis. The groups were significant differences in the level of glucose, total bilirubin (p < 0,04, p < 0,03, respectively). At the time of the examination, 57,5% of patients had steatosis, other patients had steatohepatitis. No significant differences in the level of liver function tests (ALT, AST) in the study groups were found. Significant differences were found in level of TIMP-2 (p < 0,04). TIMP-2 had a significant positive correlation with the severity of fibrosis in the hepatic tissue (rs = (0,349), p < 0,004). Conclusion. TIMP-2 may be considered as a potential non-invasive marker for the diagnosis of liver fibrosis in patients with NAFLD.

nonalcoholic fatty liver disease, fibrosis, non-invasive diagnostic, matrix metalloproteinases, tissue inhibitors of metalloproteinases

1. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis//World Gastroenterology Organisation Global Guidelines, June 2012, www.worldgastroenterology.org/NAFLD-NASH.html.

2. Драпкина О. М., Ивашкин В. Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России (Результаты открытого многоцентрового проспективного исследования-наблюдения DIREG L 01903). РЖГГК, 2014, Т. 24, № 4, С. 32-38.

3. Obesity // World Gastroenterology Organization Global Guideline, 2009, www.worldgastroenterology.org/obesity.html.

4. Qureshi K, Abrams GA. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcocholic fatty liver disease. World J Gastroenterol., 2007, no. 13, pp. 3540-3553

5. Utzschneider KM, Kahn SE. Review: The role of insulin resistance in nonalcocholic fatty liver disease. J Clin Endocrinol Metab., 2006, no. 91, pp. 4753-4761.

6. Bellentani S, Bedogni G, Tiribelli C. Liver and heart: a new link? J Hepatol., 2008, no. 49, pp. 300-302.

7. Reynaert H., Geerts A., Henrion J. The treatment of non-alcoholic steatohepatitis with thiazolidinediones. Aliment. Pharmacol. Ther., 2005, Vol. 22, N 10, P. 897-905.

8. Bacon B. R. Clinical course and prognosis of non alcoholic steatohepatitis (NASH). Falk Symposium Steatohepatitis. - Den Haag., 2000, P. 17.

9. Федоров И. Г., Никитин И. Г., Сторожаков Г. И. Неалкогольный стеатогепатит: клиника, патогенез, диагностика, лечение. Consilium medicum, 2004, Т. 6, № 6, С. 401-405.

10. Хазанов А. И. Возможности прогрессирования алкогольного и неалкогольного стеатогепатита в цирроз печени. Рос. журн. гастроэнтерол. гепатол. колопроктол., 2005, Т. 15, № 2, С. 26-32.

11. Clark J. M. The prevalense and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol., 2003, no. 98, pp. 955-956.

12. Marchesini G., Bugianesi E., Forlani G. et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology, 2003, no. 37, P. 917-923.

13. Богомолов П. О., Цодиков Г. В. Неалкогольная жировая болезнь печени. Справочник поликлинического врача, 2006, Т. 4, № 1, С. 2.

14. Kleiner D. E., Brunt E. M., Van Natta M., et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005, no. 41, P. 1313-1321.

15. Ливзан М. А., Кролевец Т. С., Лаптева И. В., Черкащенко Н. А. Неалкогольная жировая болезнь печени у лиц с абдоминальным типом ожирения. Доказательная гастроэнтерология, 2014, № 4, С. 8-14.

16. Stefanie Hemmann, Ju¨rgen Graf, Martin Roderfeld, Elke Roeb Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. Journal of Hepatology, 2007, no. 46, pp. 955-975.

17. Jun Wei Lim, John Dillon, Michael Miller Proteomic and genomic studies of non-alcocholic fatty liver disease - clues in the pathogenesis. World Journal of Gastroenterology, 2014, Vol.20, N. 26, pp. 8325-8340.

18. Ramón Bataller and David A. Brenner Liver fibrosis. J Clin Invest., 2005, Vol. 115, no. 2, pp. 209-218.

19. Yu A. S., Keeffe E. B. Rev. Nonalcoholic fatty liver disease. Gastroenterol. l Dis., 2002, Vol.2, no. 1, P.11-19.

20. Ливзан М. А., Кролевец Т. С., Лаптева И. В., Черкащенко Н. А. Лептинорезистентность у пациентов с неалкогольной жировой болезнью печени, ассоциированной с ожирением и избыточной массой тела. Медицинский совет, № 13, 2015, с. 58-62.

21. Chang Y., Ryu S., Sung E. et al. Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men. Gut., 2009, no. 58, P. 1419-1425.

22. Самородская И. В. Новая парадигма ожирения. Лечащий врач, 2014, № 12, С. 10-15.

23. Лазебник Л. Б., Звенигородская Л. А., Егорова Е. Г. Метаболический синдром с позиции гастроэнтеролога. Рус. мед. журн., 2005, Т. 13, № 26, С. 1706-1720.

24. Зилов А. В. Печень при метаболическом синдроме и инсулинорезистентности: взгляд эндокринолога. Клин. перспективы гастроэнтерол. гепатол., 2005, № 5, С. 13-17.

25. Корнеева О. Н., Драпкина О. М., Буеверов А. О., Ивашкин В. Т. Неалкогольная жировая болезнь печени как проявление метаболического синдрома. Клин. перспективы гастроэнтерол. гепатол., 2005, № 4, С. 21-24.

26. Мансуров Х. Х., Мироджов Г. К., Мансурова Ф. Х. и др. Инсулинорезистентность у больных метаболическим синдромом и желчнокаменной болезнью. Клин. мед., 2005, Т. 83, № 7, С. 48-51.

27. Alberti K. G., Zimmet P. Z. Definition, diagnosis, and classification of diabetes mellitus and its complications, part I: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet. Med., 1998, N 15, P. 539-553.

28. American Association of Clinical Endocrinologists. Medical Guidelines for the Management of Diabetes Mellitus: The AACE System of Intensive Diabetes Self-Management. Endocrine Pract., 2002, N 8, P. 40-82.

29. Reaven G. M. Role of insulin resistance in human disease. Diabetes., 1988, Vol. 37, N 12, P. 1595- 1607.

30. Medina J., Fernández-Salazar L. I., García-Buey L. et al. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care, 2004, Vol. 27, no. 8, P. 2057-2066.